Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 02 - 25 tags : Fda save search
FDA Approves Targeted Treatment for Rare Duchenne Muscular Dystrophy Mutation
Published: 2021-02-25 (Crawled : 16:36) - fda.gov
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.73%
H: 2.11%
C: 1.39%
fda treatment duchenne approval fda approval rare
Tricida Provides Update on FDA Interactions
Published: 2021-02-25 (Crawled : 22:00) - globenewswire.com
TCDA | $0.108 -22.22% 0
|
Health Technology
|
| O: -28.8%
H: 6.68%
C: -2.48%
fda
Sarepta Therapeutics Announces FDA Approval of AMONDYS 45™ (casimersen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 45
Published: 2021-02-25 (Crawled : 20:25) - globenewswire.com
SRPT | $124.27 6.11% 5.75% 1.3M
|
Health Technology
|
| O: 0.73%
H: 2.11%
C: 1.39%
treatment fda fda approval injection approval duchenne dmd
Aquestive Therapeutics Reaffirms Near-Term NDA Resubmission for Libervant™ (diazepam) Buccal Film Following FDA Feedback
Published: 2021-02-25 (Crawled : 13:00) - globenewswire.com
AQST | $3.905 -8.76% -9.6% 2.1M
|
Health Technology
|
| O: -1.0%
H: 1.29%
C: -7.18%
fda submission resubmission
HUMIRA® (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
Published: 2021-02-25 (Crawled : 01:10) - prnewswire.com
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.19%
H: 0.76%
C: -1.06%
fda fda approval approval ulcerative colitis
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.